Inhibition of bromodomain and extra‐terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia

The development of drugs able to target BTK, PI3k‐delta and BCL2 has dramatically improved chronic lymphocytic leukaemia (CLL) therapies. However, drug resistance to these therapies has already been reported due to non‐recurrent changes in oncogenic pathways and genes expression signatures. In this...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Cell Mol Med
Hauptverfasser: Carrà, Giovanna, Nicoli, Paolo, Lingua, Marcello Francesco, Maffeo, Beatrice, Cartellà, Antonio, Circosta, Paola, Brancaccio, Mara, Parvis, Guido, Gaidano, Valentina, Guerrasio, Angelo, Saglio, Giuseppe, Taulli, Riccardo, Morotti, Alessandro
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2019
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6991693/
https://ncbi.nlm.nih.gov/pubmed/31821686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.14857
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge